Clopidogrel and the concept of high-risk pharmacokinetics

Circulation. 2009 Apr 28;119(16):2127-30. doi: 10.1161/CIRCULATIONAHA.109.865907.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Aryl Hydrocarbon Hydroxylases / genetics
  • Clinical Trials as Topic
  • Clopidogrel
  • Cytochrome P-450 CYP2C19
  • Genetic Variation
  • Humans
  • Pharmacogenetics*
  • Platelet Aggregation Inhibitors / pharmacokinetics*
  • Platelet Aggregation Inhibitors / toxicity
  • Risk Factors
  • Ticlopidine / analogs & derivatives*
  • Ticlopidine / pharmacokinetics
  • Ticlopidine / toxicity

Substances

  • Platelet Aggregation Inhibitors
  • Clopidogrel
  • Aryl Hydrocarbon Hydroxylases
  • CYP2C19 protein, human
  • Cytochrome P-450 CYP2C19
  • Ticlopidine